Online inquiry

IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7257MR)

This product GTTS-WQ7257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets STAB1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_015136.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23166
UniProt ID Q9NY15
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3304MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ8558MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ6960MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ14430MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ5036MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ3369MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ7189MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW